Can-Fite BioPharma (Israel)

Recent papers from Can-Fite BioPharma (Israel)

1. A3 Adenosine Receptor Agonists as Multisystem Disease Modifiers: From Molecular Signaling to Clinical TranslationBiomolecules · 2026
2. Piclidenoson, an A3 adenosine receptor agonist, demonstrates clinical benefit in canine osteoarthritis: a pilot studyFrontiers in Veterinary Science · 2026
3. A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case reportExperimental and Therapeutic Medicine · 2024
4. Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular CarcinomaBiomedicines · 2024
5. Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial ( COMFORT ‐1)Journal of the European Academy of Dermatology and Venereology · 2024
6. Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling PathwaysBiomolecules · 2023
7. Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effectsPurinergic Signalling · 2023
8. Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study DataMolecules · 2022
9. Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical TrialCancers · 2021
10. The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in miceInternational Journal of Molecular Medicine · 2019
11. Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapyDrug Design Development and Therapy · 2019
12. Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist PiclidenosonJournal of Immunology Research · 2018
13. A3 adenosine receptor agonist, CF102, protects against hepatic ischemia/reperfusion injury following partial hepatectomyMolecular Medicine Reports · 2016
14. A3Adenosine Receptor Allosteric Modulator Induces an Anti-Inflammatory Effect:In VivoStudies and Molecular Mechanism of ActionMediators of Inflammation · 2014
15. Targeting the A3 adenosine receptor for glaucoma treatment (Review)Molecular Medicine Reports · 2013
16. CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation StudyThe Oncologist · 2012
17. Inhibition of experimental auto-immune uveitis by the A3 adenosine receptor agonist CF101International Journal of Molecular Medicine · 2011
18. Putative role of the adenosine A3 receptor in the antiproliferative action of N 6-(2-isopentenyl)adenosinePurinergic Signalling · 2011
19. Treatment of plaque‐type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trialJournal of the European Academy of Dermatology and Venereology · 2011
20. CF102 an A3 adenosine receptor agonist mediates anti‐tumor and anti‐inflammatory effects in the liverJournal of Cellular Physiology · 2010